{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:24:32Z","timestamp":1754486672915,"version":"3.41.2"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Great efforts have been made toward addressing the demand for donor kidneys. One of the most promising approaches is to use kidneys from donation after circulatory death donors. These kidneys, however, suffer from more severe ischemia and reperfusion injury than those obtained <jats:italic>via<\/jats:italic> donation after brain death and are thus more prone to develop interstitial fibrosis and tubular atrophy. Even though machine perfusion is increasingly used to reduce ischemia and reperfusion injury, there are no effective treatments available to ameliorate interstitial fibrosis and tubular atrophy, forcing patients to resume dialysis, undergo re-transplantation, or suffer from premature death. Safe and effective anti-fibrotic therapies are therefore greatly desired. We propose a new therapeutic approach in which machine perfusion solutions are supplemented with anti-fibrotic compounds. This allows the use of higher concentrations than those used in humans whilst eliminating side effects in other organs. To the authors' knowledge, no one has reviewed whether such an approach could reduce interstitial fibrosis and tubular atrophy; we therefore set out to explore its merit. In this review, we first provide background information on ischemia and reperfusion injury as well as interstitial fibrosis and tubular atrophy, after which we describe currently available approaches for preserving donor kidneys. We then present an evaluation of selected compounds. To identify promising compounds, we analyzed publications describing the effects of anti-fibrotic molecules in precision-cut kidneys slices, which are viable explants that can be cultured <jats:italic>ex vivo<\/jats:italic> for up to a few days whilst retaining functional and structural features. LY2109761, galunisertib, imatinib, nintedanib, and butaprost were shown to exert anti-fibrotic effects in slices within a relatively short timeframe (&amp;lt;48 h) and are therefore considered to be excellent candidates for follow-up <jats:italic>ex vivo<\/jats:italic> machine perfusion studies.<\/jats:p>","DOI":"10.3389\/fmed.2021.806774","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T05:12:00Z","timestamp":1641791520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Shifting Paradigms for Suppressing Fibrosis in Kidney Transplants: Supplementing Perfusion Solutions With Anti-fibrotic Drugs"],"prefix":"10.3389","volume":"8","author":[{"given":"L. Leonie","family":"van Leeuwen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri G. D.","family":"Leuvenink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Olinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchel J. R.","family":"Ruigrok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/00007890-199560120-00003","article-title":"Survival experience among elderly end-stage renal disease patients. A controlled comparison of transplantation and dialysis","volume":"60","author":"Schaubel","year":"1995","journal-title":"Transplantation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM200003023420901","article-title":"Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996","volume":"342","author":"Hariharan","year":"2000","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic Kidney Disease Diagnosis and Management","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"year":"","key":"B5"},{"key":"B6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ki.2015.88","article-title":"Kidney donation after circulatory death (DCD): state of the art","volume":"88","author":"Summers","year":"2015","journal-title":"Kidney Int."},{"key":"B7","unstructured":"2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5500\/wjt.v6.i1.103","article-title":"Renal transplantation with expanded criteria donors: Which is the optimal immunosuppression?","volume":"6","author":"Filiopoulos","year":"2016","journal-title":"World J Transplant."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1111\/j.1600-6143.2007.01993.x","article-title":"Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs","volume":"7","author":"Saidi","year":"2007","journal-title":"Am J Transplant."},{"key":"B10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.trre.2014.04.001","article-title":"The evolving approach to ethical issues in living donor kidney transplantation: a review based on illustrative case vignettes","volume":"28","author":"Venkat","year":"2014","journal-title":"Transplant Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.2215\/CJN.02270409","article-title":"The alphabet soup of kidney transplantation: SCD, DCD, ECD - Fundamentals for the practicing nephrologist","volume":"4","author":"Rao","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/j.1600-6143.2008.02414.x","article-title":"2202 kidney transplant recipients with 10 years of graft function: what happens next?","volume":"8","author":"Matas","year":"2008","journal-title":"Am J Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Strategies to improve long-term outcomes after renal transplantation","volume":"346","author":"Pascual","year":"2002","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1111\/j.1600-6143.2005.00811.x","article-title":"Kidney allograft fibrosis and atrophy early after living donor transplantation","volume":"5","author":"Cosio","year":"2005","journal-title":"Am J Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1053\/j.ajkd.2016.04.007","article-title":"Atlas of renal pathology: tubular atrophy","volume":"67","author":"Lusco","year":"2016","journal-title":"Am J Kidney Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.addr.2015.11.001","article-title":"Extracellular matrix structure","volume":"97","author":"Theocharis","year":"2016","journal-title":"Adv Drug Deliv Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.transproceed.2014.05.029","article-title":"Kidney retransplantation: removal or persistence of the previous failed allograft?","volume":"46","author":"Dinis","year":"2014","journal-title":"Transplant Proc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/MOT.0000000000000306","article-title":"Hypothermic machine perfusion in kidney transplantation","volume":"21","author":"De Deken","year":"2016","journal-title":"Curr Opin Organ Transplant."},{"key":"B19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MOT.0b013e32835ed81b","article-title":"Time to death after withdrawal of treatment in donation after circulatory death (DCD) donors","volume":"18","author":"Bradley","year":"2013","journal-title":"Curr Opin Organ Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"i108","DOI":"10.1093\/bja\/aer357","article-title":"Donation after circulatory death","volume":"108","author":"Manara","year":"2012","journal-title":"Br J Anaesth."},{"key":"B21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ki.2014.359","article-title":"The impact of cold ischemia time on renal transplant outcome","volume":"87","author":"Ponticelli","year":"2015","journal-title":"Kidney Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.kint.2015.09.002","article-title":"Prolonged warm ischemia time is associated with graft failure and mortality after kidney transplantation","volume":"89","author":"Tennankore","year":"2016","journal-title":"Kidney Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.acuroe.2011.03.007","article-title":"Is there a safe cold ischemia time interval for the renal graft?","volume":"35","author":"Barba","year":"2011","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas."},{"key":"B24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/ki.2014.304","article-title":"Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation","volume":"87","author":"Debout","year":"2015","journal-title":"Kidney Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1111\/ajt.13817","article-title":"Prolonged ischemic time, delayed graft function, and graft and patient outcomes in live donor kidney transplant recipients","volume":"16","author":"Krishnan","year":"2016","journal-title":"Am J Transplant."},{"volume-title":"Biochemistry, Oxidative Phosphorylation","year":"2021","author":"Deshpande","key":"B26"},{"volume-title":"Biochemistry, Glycolysis","year":"2021","author":"Chaudhry","key":"B27"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/ndt\/gft488","article-title":"Ischaemia-reperfusion injury: a major protagonist in kidney transplantation","volume":"29","author":"Ponticelli","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"B29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.redox.2015.08.010","article-title":"Calcium and ROS: A mutual interplay","volume":"6","author":"G\u00f6rlach","year":"2015","journal-title":"Redox Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/jcm9010253","article-title":"Ischemia and reperfusion injury in kidney transplantation: relevant mechanisms in injury and repair","volume":"9","author":"Nieuwenhuijs-Moeke","year":"2020","journal-title":"J Clin Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.34067\/KID.0004772020","article-title":"Proximal tubular oxidative metabolism in acute kidney injury and the transition to CKD","volume":"2","author":"Schaub","year":"2021","journal-title":"Kidney360."},{"key":"B32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/01.TP.0000069835.95442.9F","article-title":"Activation of mitochondrial apoptotic pathways in human renal allografts after ischemiareperfusion injury","volume":"76","author":"Castaneda","year":"2003","journal-title":"Transplantation."},{"key":"B33","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1471-4159.2011.07222.x","article-title":"Calpastatin, an endogenous calpain-inhibitor protein, regulates the cleavage of the Cdk5 activator p35 to p25","volume":"117","author":"Sato","year":"2011","journal-title":"J Neurochem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41100-017-0104-0","article-title":"Microparticles in kidney diseases: focus on kidney transplantation","volume":"3","author":"Shamekhi Amiri","year":"2017","journal-title":"Ren Replace Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1093\/ndt\/gft278","article-title":"Postconditioning ameliorates mitochondrial DNA damage and deletion after renal ischemic injury","volume":"28","author":"Tan","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2950503","DOI":"10.1155\/2016\/2950503","article-title":"Mitochondria-targeted antioxidants: future perspectives in kidney ischemia reperfusion injury","volume":"2016","author":"Kezic","year":"2016","journal-title":"Oxid Med Cell Longev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1072805","DOI":"10.1155\/2018\/1072805","article-title":"Effects of post ischemia-reperfusion treatment with trimetazidine on renal injury in rats: insights on delayed renal fibrosis progression","volume":"2018","author":"Park","year":"2018","journal-title":"Oxid Med Cell Longev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.5500\/wjt.v5.i2.52","article-title":"Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment","volume":"5","author":"Salvadori","year":"2015","journal-title":"World J Transplant."},{"key":"B39","doi-asserted-by":"publisher","first-page":"F721","DOI":"10.1152\/ajprenal.00546.2010","article-title":"Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury","volume":"300","author":"Basile","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nrneph.2011.149","article-title":"Cellular and molecular mechanisms of renal fibrosis","volume":"7","author":"Liu","year":"2011","journal-title":"Nat Rev Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3389\/fphar.2017.00855","article-title":"Drugs and targets in fibrosis","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"B42","first-page":"253","article-title":"Myofibroblast in kidney fibrosis: origin, activation, and regulation.","volume-title":"Advances in Experimental Medicine and Biology","author":"Yuan","year":"2019"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nm.3218","article-title":"Origin and function of myofibroblasts in kidney fibrosis","volume":"19","author":"LeBleu","year":"2013","journal-title":"Nat Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.bbadis.2013.01.022","article-title":"Bone marrow contributions to fibrosis","volume":"1832","author":"Mackinnon","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"B45","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fphys.2016.00061","article-title":"Role of bone marrow-derived fibroblasts in renal fibrosis","volume":"7","author":"Yan","year":"2016","journal-title":"Front Physiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.3390\/ijms20246326","article-title":"Kidney cells regeneration: dedifferentiation of tubular epithelium, resident stem cells and possible niches for renal progenitors.","volume":"20","author":"Andrianova","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"a005058","DOI":"10.1101\/cshperspect.a005058","article-title":"Extracellular matrix degradation and remodeling in development and disease","volume":"3","author":"Lu","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1369\/0022155419849388","article-title":"Extracellular matrix in kidney fibrosis: more than just a scaffold","volume":"67","author":"B\u00fclow","year":"2019","journal-title":"J Histochem Cytochem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.3390\/ijms19092532","article-title":"Targeting TGF-\u03b2 signaling in kidney fibrosis","volume":"19","author":"Isaka","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00467-015-3169-4","article-title":"Tubular atrophy in the pathogenesis of chronic kidney disease progression","volume":"31","author":"Schelling","year":"2016","journal-title":"Pediatric Nephrol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1755-1536-7-15","article-title":"Recent advances in renal interstitial fibrosis and tubular atrophy after kidney transplantation","volume":"7","author":"Li","year":"2014","journal-title":"Fibrogenesis Tissue Repair."},{"key":"B52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/aps.2017.182","article-title":"Organ preservation: from the past to the future","volume":"39","author":"Jing","year":"2018","journal-title":"Acta Pharmacol Sin."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003845","article-title":"Hypothermic machine perfusion as a national standard preservation method for deceased donor kidneys","author":"Brat","year":"2021","journal-title":"Transplantation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/MOT.0000000000000215","article-title":"Novel preservation methods to increase the quality of older kidneys","volume":"20","author":"Brat","year":"2015","journal-title":"Curr Opin Organ Transplant."},{"key":"B55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/TP.0000000000003679","article-title":"Advances in kidney preservation techniques and their application in clinical practice","volume":"105","author":"Hosgood","year":"2021","journal-title":"Transplantation"},{"key":"B56","first-page":"1","article-title":"Normothermic machine perfusion of the liver.","volume-title":"Methods in Bioengineering : Organ Preservation and Reengineering.","author":"Vogel","year":"2011"},{"key":"B57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/TP.0b013e3181c343a5","article-title":"Acceptable outcome after kidney transplantation using \u201cexpanded criteria donor\u201d grafts","volume":"89","author":"Fraser","year":"2010","journal-title":"Transplantation."},{"key":"B58","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1432-2277.2009.01047.x","article-title":"Machine perfusion or cold storage in organ transplantation: indication, mechanisms, and future perspectives","volume":"23","author":"Yuan","year":"2010","journal-title":"Transpl Int."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/01.TP.0000159143.45022.F6","article-title":"UW solution for hypothermic machine perfusion of warm ischemic kidneys","volume":"79","author":"Lindell","year":"2005","journal-title":"Transplantation."},{"key":"B60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7182\/pit2014384","article-title":"Preservation of kidneys by machine perfusion influences gene expression and may limit ischemia\/reperfusion injury","volume":"24","author":"Wszola","year":"2014","journal-title":"Prog Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/S1743-9191(13)60029-1","article-title":"Impact of static cold storage VS hypothermic machine preservation on ischemic kidney graft: inflammatory cytokines and adhesion molecules as markers of ischemia\/reperfusion tissue damage. Our preliminary results","volume":"11","author":"Tozzi","year":"2013","journal-title":"Int J Surg."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8572138","DOI":"10.1155\/2019\/8572138","article-title":"Influence of hypoxic preservation temperature on endothelial cells and kidney integrity","volume":"2019","author":"Giraud","year":"2019","journal-title":"Biomed Res Int"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMoa0802289","article-title":"Machine perfusion or cold storage in deceased-donor kidney transplantation","volume":"360","author":"Moers","year":"2009","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOT.0b013e32835e29de","article-title":"Hypothermic reconditioning in organ transplantation","volume":"18","author":"Minor","year":"2013","journal-title":"Curr Opin Organ Transplant."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1097\/TP.0000000000002728","article-title":"Effects of oxygen during long-term hypothermic machine perfusion in a porcine model of kidney donation after circulatory death","volume":"103","author":"Venema","year":"2019","journal-title":"Transplantation"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jss.2013.04.071","article-title":"Benefits of active oxygenation during hypothermic machine perfusion of kidneys in a preclinical model of deceased after cardiac death donors","volume":"184","author":"Thuillier","year":"2013","journal-title":"J Surg Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(20)32411-9","article-title":"Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial","volume":"396","author":"Jochmans","year":"2020","journal-title":"Lancet."},{"key":"B68","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1097\/TP.0b013e3181f5c40c","article-title":"The value of machine perfusion perfusate biomarkers for predicting kidney transplant outcome","volume":"90","author":"Moers","year":"2010","journal-title":"Transplantation."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/tri.13984","article-title":"Proteomic analysis of machine perfusion solution from brain dead donor kidneys reveals that elevated complement, cytoskeleton and lipid metabolism proteins are associated with 1-year outcome","volume":"34","author":"van Leeuwen","year":"2021","journal-title":"Transpl Int"},{"key":"B70","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.kint.2021.04.001","article-title":"Metabolic needs of the kidney graft undergoing normothermic machine perfusion","volume":"100","author":"Arykbaeva","year":"2021","journal-title":"Kidney Int"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003817","article-title":"Renal normothermic machine perfusion","author":"Hamelink","year":"2021","journal-title":"Transplantation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/TP.0000000000002967","article-title":"Renal protection against ischemia reperfusion injury: hemoglobin-based oxygen carrier-201 versus blood as an oxygen carrier in ex vivo subnormothermic machine perfusion","volume":"104","author":"Bhattacharjee","year":"2020","journal-title":"Transplantation."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003940","article-title":"Impact of red blood cells on function and metabolism of porcine deceased donor kidneys during normothermic machine perfusion","author":"Venema","year":"2021","journal-title":"Transplantation"},{"key":"B74","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1097\/TP.0000000000001343","article-title":"Continuous normothermic ex vivo kidney perfusion improves graft function in donation after circulatory death pig kidney transplantation","volume":"101","author":"Kaths","year":"2017","journal-title":"Transplantation"},{"key":"B75","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/ajt.14059","article-title":"Continuous normothermic ex vivo kidney perfusion is superior to brief normothermic perfusion following static cold storage in donation after circulatory death pig kidney transplantation","volume":"17","author":"Kaths","year":"2017","journal-title":"Am J Transplant"},{"key":"B76","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/TP.0000000000003066","article-title":"Normothermic ex vivo kidney perfusion improves early DCD graft function compared with hypothermic machine perfusion and static cold storage","volume":"104","author":"Urbanellis","year":"2020","journal-title":"Transplantation"},{"key":"B77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jss.2017.04.008","article-title":"Comparison of normothermic and hypothermic perfusion in porcine kidneys donated after cardiac death","volume":"216","author":"Blum","year":"2017","journal-title":"J Surg Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/bjs.10733","article-title":"Normothermic machine perfusion for the assessment and transplantation of declined human kidneys from donation after circulatory death donors","volume":"105","author":"Hosgood","year":"2018","journal-title":"Br J Surg."},{"key":"B79","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/TP.0b013e31822d4e04","article-title":"First in man renal transplantation after ex vivo normothermic perfusion","volume":"92","author":"Hosgood","year":"2011","journal-title":"Transplantation."},{"key":"B80","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/ajt.14932","article-title":"Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation","volume":"19","author":"Weissenbacher","year":"2019","journal-title":"Am J Transplant"},{"key":"B81","doi-asserted-by":"publisher","first-page":"F117","DOI":"10.1152\/ajprenal.00108.2019","article-title":"Inhibition of tyrosine kinase receptor signaling attenuates fibrogenesis in an ex vivo model of human renal fibrosis","volume":"318","author":"Bigaeva","year":"2020","journal-title":"Am J Physiol Physiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2016.06.057","article-title":"Renal fibrosis in precision-cut kidney slices","volume":"790","author":"Stribos","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3389\/fphys.2017.01026","article-title":"Murine precision-cut kidney slices as an ex vivo model to evaluate the role of transforming growth factor-\u03b21 signaling in the onset of renal fibrosis","volume":"8","author":"Stribos","year":"2017","journal-title":"Front Physiol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"165582","DOI":"10.1016\/j.bbadis.2019.165582","article-title":"Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices","volume":"1866","author":"Bigaeva","year":"2020","journal-title":"Biochim Biophys Acta"},{"key":"B85","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3390\/pharmaceutics12050459","article-title":"Predictive value of precision-cut kidney slices as an ex vivo screening platform for therapeutics in human renal fibrosis","volume":"12","author":"Bigaeva","year":"2020","journal-title":"Pharmaceutics"},{"key":"B86","doi-asserted-by":"publisher","first-page":"13291","DOI":"10.1111\/apha.13291","article-title":"Activation of the prostaglandin E2 EP2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices","volume":"227","author":"Jensen","year":"2019","journal-title":"Acta Physiol."},{"key":"B87","first-page":"4923","article-title":"LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells","volume":"8","author":"Gao","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.18632\/oncotarget.23193","article-title":"Mechanism of action and efficacy of LY2109761, a TGF-\u03b2 receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE","volume":"9","author":"He","year":"2018","journal-title":"Oncotarget."},{"key":"B89","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/1535-7163.MCT-07-0337","article-title":"LY2109761, a novel transforming growth factor \u03b2 receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis","volume":"7","author":"Melisi","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/cbin.10788","article-title":"M2 macrophages induce EMT through the TGF-\u03b2\/Smad2 signaling pathway","volume":"41","author":"Zhu","year":"2017","journal-title":"Cell Biol Int"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1158\/1078-0432.CCR-11-2855","article-title":"LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-\u03b2 and BMP-associated proinflammatory and proangiogenic signals","volume":"18","author":"Flechsig","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000086043","volume-title":"Heat Shock Protein 47 and Renal Fibrogenesis. In: Cellular Stress Responses in Renal Diseases","author":"Razzaque","year":"2005"},{"key":"B93","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.18632\/oncotarget.23795","article-title":"Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-\u03b2 receptor type I inhibitor","volume":"9","author":"Yingling","year":"2018","journal-title":"Oncotarget."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1111\/bph.13945","article-title":"Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis","volume":"174","author":"Luangmonkong","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1007\/s00204-018-2231-y","article-title":"Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model","volume":"92","author":"Hammad","year":"2018","journal-title":"Arch Toxicol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3892\/ijmm.2020.4594","article-title":"Promotion of liver regeneration and anti-fibrotic effects of the TGF-\u03b2 receptor kinase inhibitor galunisertib in CCl4-treated mice","volume":"46","author":"Masuda","year":"2020","journal-title":"Int J Mol Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S0959-8049(02)80600-1","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"Buchdunger","year":"2002","journal-title":"Eur J Cancer."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.04-2370com","article-title":"Imatinib mesylate blocks a non-Smad TGF-\u03b2 pathway and reduces renal fibrogenesis in vivo","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J"},{"key":"B100","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1084\/jem.20041393","article-title":"Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis","volume":"201","author":"Abdollahi","year":"2005","journal-title":"J Exp Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1042\/CS20170134","article-title":"Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease","volume":"131","author":"Liu","year":"2017","journal-title":"Clin Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1111\/1759-7714.13437","article-title":"Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: a case report and literature review","volume":"11","author":"Shiratori","year":"2020","journal-title":"Thorac Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.resinv.2020.01.003","article-title":"Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-\u03b2\/Smad pathway","volume":"58","author":"Ihara","year":"2020","journal-title":"Respir Investig"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.3390\/ijms20143607","article-title":"Infusing mesenchymal stromal cells into porcine kidneys during normothermic machine perfusion: intact MSCs can be traced and localised to Glomeruli","volume":"20","author":"Pool","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B106","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1126\/scitranslmed.aam6764","article-title":"Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys","volume":"9","author":"Tietjen","year":"2017","journal-title":"Sci Transl Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","article-title":"Stability of protein pharmaceuticals: an update","volume":"27","author":"Manning","year":"2010","journal-title":"Pharm Res."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.806774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T05:12:20Z","timestamp":1641791540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.806774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":107,"alternative-id":["10.3389\/fmed.2021.806774"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.806774","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"article-number":"806774"}}